Table 2.
Clinical characteristics
| Patients n | Sex/Age (y) | Previous treatment | Response to FCR | Response to RIT | Follow up (mo) since RIT |
|---|---|---|---|---|---|
| 1 | F/68 | CHOP/R,radiotherapy | CR | CR | 104 alive in CR |
| 2 | F/66 | Radiotherapy, CHOP/R | CR | CR | 88 alive in CR |
| 3 | F/57 | CHOP/R | PR | CR | 99 alive in CR |
| 4 | F/67 | CHOP/R, radiotherapy | CR | CR | 13 dead in CR |
| 5 | M/46 | CHOP/like, ASCT, IFN maintenance for 24 months | PR | CR | 83 alive in CR |
| 6 | F/61 | MACOPB/R | CR | CR | 92 alive in CR |
| 7 | M/69 | CHOP, FM/R, CyDex/R | CR | CR | 30 dead in CR (t-MDS) |
| 8 | M/57 | Chlorambucil, MACOPB/R | CR | CR | 32 dead in CR |
| 9 | F/77 | Chlorambucil, radiotherapy | CR | CR | 99 alive in CR |
CHOP cyclophosfamide, doxorubicin, vincristine, prednisone; R Rituximab; MACOPB Methotrexate, Doxorubicin, cyclophoshamide, vincristine, prednisone, bleomycin; ASCT autologous stem cell transplantation; IFN alpha interferon, FM fludarabine, mitoxantrone; Cy Dex cyclophosphamide, dexamethasone; t-MDS treatment-related myelodysplastic syndrome